View in EDS HTML Full Text PDF Full Text

Is there a rationale for hyperbaric oxygen therapy in the patients with Post COVID syndrome?: A critical review.

Saved in:
Bibliographic Details
Title: Is there a rationale for hyperbaric oxygen therapy in the patients with Post COVID syndrome?: A critical review.
Authors: Pawlik, MT (AUTHOR), Rinneberg, G (AUTHOR), Koch, A (AUTHOR), Meyringer, H (AUTHOR), Loew, TH (AUTHOR), Kjellberg, A (AUTHOR)
Source: European Archives of Psychiatry & Clinical Neuroscience. Dec2024, Vol. 274 Issue 8, p1797-1817. 21p.
Subjects: Post-acute COVID-19 syndrome, Hyperbaric oxygenation, COVID-19 pandemic, Microbiota, Chronic fatigue syndrome
Abstract: The SARS-CoV-2 pandemic has resulted in 762 million infections worldwide from 2020 to date, of which approximately ten percent are suffering from the effects after infection in 2019 (COVID-19) [1, 40]. In Germany, it is now assumed that at least one million people suffer from post-COVID condition with long-term consequences. These have been previously reported in diseases like Myalgic Encephalomyelitis (ME) and Chronic Fatigue Syndrome (CFS). Symptoms show a changing variability and recent surveys in the COVID context indicate that 10–30 % of outpatients, 50 to 70% of hospitalised patients suffer from sequelae. Recent data suggest that only 13% of all ill people were completely free of symptoms after recovery [3, 9]. Current hypotheses consider chronic inflammation, mitochondrial dysfunction, latent viral persistence, autoimmunity, changes of the human microbiome or multilocular sequelae in various organ system after infection. Hyperbaric oxygen therapy (HBOT) is applied since 1957 for heart surgery, scuba dive accidents, CO intoxication, air embolisms and infections with anaerobic pathogens. Under hyperbaric pressure, oxygen is physically dissolved in the blood in higher concentrations and reaches levels four times higher than under normobaric oxygen application. Moreover, the alternation of hyperoxia and normoxia induces a variety of processes at the cellular level, which improves oxygen supply in areas of locoregional hypoxia. Numerous target gene effects on new vessel formation, anti-inflammatory and anti-oedematous effects have been demonstrated [74]. The provision of intermittently high, local oxygen concentrations increases repair and regeneration processes and normalises the predominance of hyperinflammation. At present time only one prospective, randomized and placebo-controlled study exists with positive effects on global cognitive function, attention and executive function, psychiatric symptoms and pain interference. In conclusion, up to this date HBO is the only scientifically proven treatment in a prospective randomized controlled trial to be effective for cognitive improvement, regeneration of brain network and improvement of cardiac function. HBOT may have not only theoretical but also potential impact on targets of current pathophysiology of Post COVID condition, which warrants further scientific studies in patients. [ABSTRACT FROM AUTHOR]
Copyright of European Archives of Psychiatry & Clinical Neuroscience is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 180988886
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Is there a rationale for hyperbaric oxygen therapy in the patients with Post COVID syndrome?: A critical review.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Pawlik%2C+MT%22">Pawlik, MT</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Rinneberg%2C+G%22">Rinneberg, G</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Koch%2C+A%22">Koch, A</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Meyringer%2C+H%22">Meyringer, H</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Loew%2C+TH%22">Loew, TH</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kjellberg%2C+A%22">Kjellberg, A</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22European+Archives+of+Psychiatry+%26+Clinical+Neuroscience%22">European Archives of Psychiatry & Clinical Neuroscience</searchLink>. Dec2024, Vol. 274 Issue 8, p1797-1817. 21p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Post-acute+COVID-19+syndrome%22">Post-acute COVID-19 syndrome</searchLink><br /><searchLink fieldCode="DE" term="%22Hyperbaric+oxygenation%22">Hyperbaric oxygenation</searchLink><br /><searchLink fieldCode="DE" term="%22COVID-19+pandemic%22">COVID-19 pandemic</searchLink><br /><searchLink fieldCode="DE" term="%22Microbiota%22">Microbiota</searchLink><br /><searchLink fieldCode="DE" term="%22Chronic+fatigue+syndrome%22">Chronic fatigue syndrome</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: The SARS-CoV-2 pandemic has resulted in 762 million infections worldwide from 2020 to date, of which approximately ten percent are suffering from the effects after infection in 2019 (COVID-19) [1, 40]. In Germany, it is now assumed that at least one million people suffer from post-COVID condition with long-term consequences. These have been previously reported in diseases like Myalgic Encephalomyelitis (ME) and Chronic Fatigue Syndrome (CFS). Symptoms show a changing variability and recent surveys in the COVID context indicate that 10–30 % of outpatients, 50 to 70% of hospitalised patients suffer from sequelae. Recent data suggest that only 13% of all ill people were completely free of symptoms after recovery [3, 9]. Current hypotheses consider chronic inflammation, mitochondrial dysfunction, latent viral persistence, autoimmunity, changes of the human microbiome or multilocular sequelae in various organ system after infection. Hyperbaric oxygen therapy (HBOT) is applied since 1957 for heart surgery, scuba dive accidents, CO intoxication, air embolisms and infections with anaerobic pathogens. Under hyperbaric pressure, oxygen is physically dissolved in the blood in higher concentrations and reaches levels four times higher than under normobaric oxygen application. Moreover, the alternation of hyperoxia and normoxia induces a variety of processes at the cellular level, which improves oxygen supply in areas of locoregional hypoxia. Numerous target gene effects on new vessel formation, anti-inflammatory and anti-oedematous effects have been demonstrated [74]. The provision of intermittently high, local oxygen concentrations increases repair and regeneration processes and normalises the predominance of hyperinflammation. At present time only one prospective, randomized and placebo-controlled study exists with positive effects on global cognitive function, attention and executive function, psychiatric symptoms and pain interference. In conclusion, up to this date HBO is the only scientifically proven treatment in a prospective randomized controlled trial to be effective for cognitive improvement, regeneration of brain network and improvement of cardiac function. HBOT may have not only theoretical but also potential impact on targets of current pathophysiology of Post COVID condition, which warrants further scientific studies in patients. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of European Archives of Psychiatry & Clinical Neuroscience is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=180988886
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s00406-024-01911-y
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 21
        StartPage: 1797
    Subjects:
      – SubjectFull: Post-acute COVID-19 syndrome
        Type: general
      – SubjectFull: Hyperbaric oxygenation
        Type: general
      – SubjectFull: COVID-19 pandemic
        Type: general
      – SubjectFull: Microbiota
        Type: general
      – SubjectFull: Chronic fatigue syndrome
        Type: general
    Titles:
      – TitleFull: Is there a rationale for hyperbaric oxygen therapy in the patients with Post COVID syndrome?: A critical review.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Pawlik, MT
      – PersonEntity:
          Name:
            NameFull: Rinneberg, G
      – PersonEntity:
          Name:
            NameFull: Koch, A
      – PersonEntity:
          Name:
            NameFull: Meyringer, H
      – PersonEntity:
          Name:
            NameFull: Loew, TH
      – PersonEntity:
          Name:
            NameFull: Kjellberg, A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: Dec2024
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 09401334
          Numbering:
            – Type: volume
              Value: 274
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: European Archives of Psychiatry & Clinical Neuroscience
              Type: main
ResultId 1